- Two abstracts will be presented in a pre-recorded poster presentation and oral session
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that two abstracts have been accepted for a poster presentation and an oral session at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in person in Atlanta, Georgia and virtually from December 11-14, 2021. The poster will focus on the Company’s shRNA-based anti-BCMA allogeneic CAR T candidate CYAD-211 for the treatment of relapsed/refractory (r/r) multiple myeloma (r/r MM). The oral session will focus on the Company’s autologous NKG2D receptor-based CAR T candidate CYAD-02 for the treatment of r/r acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In addition, the abstracts will be published online in the November supplemental issue of peer-reviewed journal Blood.
ASH 2021 Presentation Details:
The following abstracts published today are now available on the ASH conference website. Following their presentation at the meeting, the posters will be available in the Scientific Publications section of Celyad Oncology’s website.
Publication #2817: IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T Cell Therapy Platform
Session Name: 704. Cellular Immunotherapies: Clinical: Poster II – Poster presentation
Date: Sunday, December 12, 2021, from 6:00 p.m. to 8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Publication #408: Co-expression of an shRNA Targeting MICA/MICB Improves the Clinical Activity of a NKG2D-based CAR T In Patients with Relapsed / Refractory AML/MDS
Session Name: 703. Cellular Immunotherapies: Basic and Translational II – Oral session
Date: Sunday, December 12, 2021
Presentation Time: 10:45 a.m. ET
Location: Georgia World Congress Center, Room B405-407
